Articles

Long-term, regular use of aspirin was associated with reduced risk for death from any cause, as well as death from cancer, in a very large observational study reported at the 2017 Annual Meeting of the American Association for Cancer Research. Read More ›

Unanticipated cardiotoxicity occurs in an estimated 3.5% of patients with hematologic malignancies secondary to the use of targeted therapies. Read More ›

Trends in the adoption of electronic health records (EHRs) show increasing use of advanced functionality. More providers are now using more advanced EHRs that include electronic clinical information and computerized entry of provider orders, as well as results management and decision support. Read More ›

Immunotherapy is a hot topic in oncology, with hundreds of ongoing clinical trials. As more patients are treated with checkpoint inhibitors, nurses will play a key role in the management of these patients. Read More ›

Five-year analysis of the phase 3 ALTTO trial showed no decided benefit to dual HER2 blockade over single-agent HER2-targeted therapy for the treatment of HER2-positive early-stage breast cancer. However, an indication for dual HER2 blockade use in HER2-positive, estrogen receptor–negative tumors is a possibility. Read More ›

A modest reduction in the risk for invasive breast cancer was achieved by adding a second HER2-targeted agent to the treatment regimen for women with early-stage HER2+ breast cancer. The results suggest that the strategy may be appropriate in women at highest risk for recurrence. Read More ›

Single-agent pembrolizumab produced durable responses in women with metastatic triple-negative breast cancer who have received prior chemotherapy for metastatic disease. Read More ›

A 9-week course of trastuzumab as adjuvant therapy in women with hormone receptor–positive, early-stage breast cancer can maintain efficacy and reduce toxicity compared with the standard 1-year course of trastuzumab. Read More ›

Two additional trastuzumab biosimilar agents demonstrate therapeutic equivalence to trastuzumab in women with HER2-positive breast cancer. Read More ›